Work

Sa1711 - Real World Comparative Risk of Serious Infection with Adalimumab, Vedolizumab, and Infliximab in Patients with Inflammatory Bowel Disease

Year: 2018

Type: conference-abstract

Source: Gastroenterology

DOI: 10.1016/s0016-5085(18)31535-x

Authors: Mark T. Osterman, Millie D. Long, Siddharth Singh, Nicole Meyer, Chaoling Feng, Kate Higgins, Zsolt Hepp, Dilek Arikan, Anthony Wang, Brian G. Feagan

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2801962232

Cites:

Cited by: 4

Related to: 10